KATELYNN CATALDO: Open Payments
NPI 1962836155 · WORCESTER, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,713 in 130 payments from 19 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $2,713
Food & beverage: $2,713
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 20 | $440 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $360 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 21 | $319 |
| GENZYME CORPORATION | 7 | $197 |
| Madrigal Pharmaceuticals | 6 | $197 |
| Gilead Sciences, Inc. | 7 | $185 |
| ABBVIE INC. | 13 | $181 |
| Phathom Pharmaceuticals, Inc. | 7 | $164 |
| Ipsen Biopharmaceuticals, Inc | 4 | $115 |
| Ardelyx, Inc. | 6 | $103 |
Products named: TREMFYA, XIFAXAN, DUPIXENT, ENTYVIO, REZDIFFRA, VOQUEZNA, IQIRVO, IBSRELA.
Industry payments across MA — which companies pay providers there.
